Dissection of the biphasic nature of hypoxia-induced motogenic action in bone marrow-derived human mesenchymal stem cells

Stem Cells

Volumn 29, Issue 6, 2011, Pages 952-963

  Busletta, Chiara ^a   Novo, Erica ^a   Valfrè Di Bonzo, Lorenzo ^a   Povero, Davide ^a   Paternostro, Claudia ^a   Ievolella, Monica ^a   Mareschi, Katia ^a,b   Ferrero, Ivana ^a,b   Cannito, Stefania ^a   Compagnone, Alessandra ^a   Bandino, Andrea ^a   Colombatto, Sebastiano ^a   Fagioli, Franca ^b   Parola, Maurizio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

Chemotaxis; Human mesenchymal stem cells; Hypoxia; Hypoxia inducible factor; Migration; Reactive oxygen species

Indexed keywords

5' NUCLEOTIDASE; BETA1 INTEGRIN; ENDOGLIN; HYPOXIA INDUCIBLE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; THY 1 ANTIGEN; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BONE MARROW; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYPOXIA; MESENCHYMAL STEM CELL; MOLECULAR MECHANICS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WOUND HEALING;

ANTIGENS, CD; BONE MARROW CELLS; CELL HYPOXIA; CELL MOVEMENT; CELLS, CULTURED; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MESENCHYMAL STEM CELLS; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN STABILITY; REACTIVE OXYGEN SPECIES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957614930     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.642     Document Type: Article

References (45)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic cells. Science 1997;276:71-74. (Pubitemid 27161245)
2. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147. (Pubitemid 29282067)
3. Pereira RF, Halford KW, O'Hara MD et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 1995;92:4857-4861.
4. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL-1α. J Cell Physiol 1996;166:585-592. (Pubitemid 26095485)
5. Yoo JU, Barthel TS, Nishimura K et al. The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. J Bone Joint Surg Am 1998;80:1745-1757. (Pubitemid 29013807)
6. Park SR, Oreffo RO, Triffitt JT. Interconversion potential of cloned human marrow adipocytes in vitro. Bone 1999;24:549-554. (Pubitemid 29234067)
7. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995;18:1417-1426.
8. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20. (Pubitemid 38931831)
9. Al-Khaldi A, Al-Sabti H, Galipeau J et al. Therapeutic angiogenesis using autologous bone marrow stromal cells: Improved blood flow in a chronic limb ischemia model. Ann Thorac Surg 2003;75:204-209. (Pubitemid 36099048)
10. Nagakami H, Maeda K, Morishita R et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005;25:2542-2547. (Pubitemid 43732276)
11. Sordi V, Malosio ML, Marchesi F et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005;106:419-427. (Pubitemid 40981232)
12. Son BR, Marquez-Curtis LA, Kucia M et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006;24:1254-1264. (Pubitemid 44464694)
13. Jaganathan BG, Ruester B, Dressel L et al. Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells 2007;25:1966-1974. (Pubitemid 47258174)
14. Ponte AL, Marais E, Gallay N et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007;25:1737-1745. (Pubitemid 47121852)
15. Zwezdaryk KJ, Coffelt SB, Figueroa YG et al. Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. Exp Hematol 2007;35:640-652. (Pubitemid 46427969)
16. Tomchuck SL, Zwezdaryk KJ, Coffelt SB et al. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008;26:99-107.
17. Tondreau T, Meuleman N, Stamatopoulos B et al. In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: The role of their migration in injured tissues. Cytotherapy 2009;11:559-569.
18. Sordi V. Mesenchymal stem cell homing capacity. Transplantation 2009;87:S42-S45.
19. Koh SH, Noh MY, Cho GW et al. Erythropoietin increases the motility of human bone marrow-multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev 2009;18:411-421.
20. Xu F, Shi J, Yu B et al. Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro. Oncol Rep 2010;23:1561-1567.
21. Valfrè di Bonzo L, Ferrero I, Cravanzola C et al. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: Engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 2008;57:223-231. (Pubitemid 351158051)
22. Novo E, Busletta C, Valfrè di Bonzo L et al. Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic profibrogenic cells. J Hepatol 2011;54:964-974.
23. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-472. (Pubitemid 46660978)
24. Mayumdar J, Dondeti V, Simon MC. Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med 2009;13:4319-4328.
25. Rochefort GY, Delorme B, Lopez A et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 2006;24:2202-2208. (Pubitemid 44527473)
26. Rosova I, Dao M, Capoccia B et al. Hypoxic preconditioning results in increate motility and improve therapeutic potential of human mesenchymal stem cells. Stem Cells 2008;26:2173-2182.
27. Lee SH, Lee YJ, Song CH et al. Role of FAK phosphorylation in hypoxia-induced hMSCs migration: Involvement of VEGF as well as MAPKs and eNOS pathways. Am J Physiol Cell Physiol 2010;298:C847-C856.
28. Ferrero I, Mazzini L, Rustichelli D et al. Bone marrow mesenchymal stem cells isolated from healthy donors and sporadic amyotrophic lateral sclerosis patients. Cell Transplant 2008;17:255-266. (Pubitemid 351717329)
29. Novo E, Cannito S, Zamara E et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007;170:1942-1953. (Pubitemid 47339268)
30. Novo E, Marra F, Zamara E et al. Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut 2006;55:90-97. (Pubitemid 41820641)
31. Zamara E, Novo E, Marra F et al. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004;40:60-68. (Pubitemid 38067269)
32. Gururajan M, Chui R, Karuppannan AK et al. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005;106:1382-1391. (Pubitemid 41129605)
33. Novo E, Marra F, Zamara E et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: Resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006;55:1174-1182. (Pubitemid 44085687)
34. Cannito S, Novo E, Compagnone A et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008;29:2267-2278.
35. Kietzmann T, Görlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 2005;16:474-486.
36. Guzy RD, Hoyos B, Robin E et al. Mitochondrial complex III is required for hypoxia induced ROS production and cellular oxygen sensing. Cell Metab 2005;1:401-408. (Pubitemid 43960623)
37. Novo E, Valfrè di Bonzo L, Busletta C et al. Hypoxia-induced migration of hepatic stellate cells and bone marrow-derived mesenchymal stem cells involves common redox mechanisms. J Hepatol 2009; 50(suppl 1):S112, Abstract 285.
38. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: The paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006;91:807-819. (Pubitemid 44266577)
39. Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Diff 2008;15:660-666. (Pubitemid 351405069)
40. Barr RK, Bogoyevitch MA. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol 2001;33:1047-1063. (Pubitemid 32817087)
41. Temkin V, Karin M. From death receptor to reactive oxygen species and c-Jun N terminal protein kinase: The receptor-interacting protein 1 odyssey. Immunol Rev 2007;220:8-21. (Pubitemid 350045563)
42. Novo E, Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 2008;1:5.
43. Xia Y, Karin M. The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol 2004;14:94-101. (Pubitemid 38186643)
44. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669. (Pubitemid 351615417)
45. Parola M, Marra F, Pinzani M. Myofibroblast-like cells in liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol Asp Med 2008;29:58-66. (Pubitemid 351312216)